drugset
drugset / Trial / NCT04194892

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants

NCT04194892 ↗

Phase 1 Completed 12 enrolled Eli Lilly and Company ARMO BioSciences · collab
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to assess how fast pegilodecakin gets into the blood stream and how long it takes the body to remove it, when given as a solution formulation via a prefilled syringe (PFS) versus from a vial drawn into a conventional syringe. Information about side effects will be collected. The study is open to healthy participants. Total participant duration in trial is approximately 42 days.

Timeline

Start
2018-01-19
Primary completion
2018-03-14
Completion
2018-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegilodecakin Protein / enzyme biologic 0.8 mg Subcutaneous

Indications

No indication recorded.